Glenn Boehnlein - Stryker CFO, Vice President

SYK Stock  EUR 371.20  8.40  2.32%   

President

Mr. Glenn S. Boehnlein is Chief Financial Officer, Vice President of the Company. He has global responsibilities for Finance activities, including Corporationrationrate Accounting, Reporting, Tax, Treasury and Internal Audit since 2016.
Age 61
Tenure 8 years
Phone269 385 2600
Webhttps://www.stryker.com
Boehnlein began his career with us in 2003 as the Vice President of Finance and IT for our Endoscopy division and has taken on roles of increasing responsibility throughout his career, most recently as Group CFO of MedSurg and Neurotechnology. Prior to joining us, Mr. Boehnlein spent three years with Success TV as CFO. Prior to that, he was a partner and certified public accountant at Arthur Andersen. He received his bachelor’s and master’s degrees in accounting from Mississippi State University.

Stryker Management Efficiency

The company has return on total asset (ROA) of 0.0618 % which means that it generated a profit of $0.0618 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1498 %, meaning that it generated $0.1498 on every $100 dollars invested by stockholders. Stryker's management efficiency ratios could be used to measure how well Stryker manages its routine affairs as well as how well it operates its assets and liabilities.
Stryker has accumulated 11.86 B in total debt with debt to equity ratio (D/E) of 74.2, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Stryker has a current ratio of 2.03, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Stryker until it has trouble settling it off, either with new capital or with free cash flow. So, Stryker's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Stryker sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Stryker to invest in growth at high rates of return. When we think about Stryker's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 4 records

PRESIDENT Age

William LeatherberryNMI Holdings
52
Andrew PeytonSuperior Plus Corp
55
Adam PollitzerNMI Holdings
43
John SwensonNMI Holdings
N/A
Stryker Corporation operates as a medical technology company. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan. STRYKER CORP operates under Medical Devices classification in Germany and is traded on Frankfurt Stock Exchange. It employs 36000 people. Stryker (SYK) is traded on Frankfurt Exchange in Germany and employs 51,000 people.

Management Performance

Stryker Leadership Team

Elected by the shareholders, the Stryker's board of directors comprises two types of representatives: Stryker inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Stryker. The board's role is to monitor Stryker's management team and ensure that shareholders' interests are well served. Stryker's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Stryker's outside directors are responsible for providing unbiased perspectives on the board's policies.
Robert Cohen, CTO Replacement
Alan Douville, Chief VP
Kevin Lobo, President CEO, Director
Glenn Boehnlein, CFO, Vice President
Jason Beach, VP Relations
Spencer Stiles, Group Spine
Viju Menon, Group President - Global Quality and Business Operations
Andrew Pierce, Group Neurotechnology
William Berry, Principal Accounting Officer, Vice President Corporate Controller
Timothy Scannell, Group President - MedSurg and Neurotechnology

Stryker Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Stryker a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Additional Information and Resources on Investing in Stryker Stock

When determining whether Stryker is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Stryker Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Stryker Stock. Highlighted below are key reports to facilitate an investment decision about Stryker Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Stryker. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more detail on how to invest in Stryker Stock please use our How to Invest in Stryker guide.
You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Please note, there is a significant difference between Stryker's value and its price as these two are different measures arrived at by different means. Investors typically determine if Stryker is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Stryker's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.